Neuren Pharmaceuticals (ASX:NEU) has updated investors on the 2024 earnings announcement and conference call of its partner, Acadia Pharmaceuticals.
Acadia announced 2024 net sales of Neuren's DAYBUE (trofinetide) in the US of US$348.4 million, up 97 per cent from 2023, and towards the top of its previous guidance range of US$340-350 million.
Fourth quarter net sales of US$96.7 million was a record quarter since DAYBUE's launch in April 2023.
Neuren said that with 70 per cent of the 5,500 to 5,800 diagnosed Rett patients yet to try DAYBUE, there is substantial potential for growth in the US. Acadia is expanding its field force by approximately 30 per cent, optimising patient support, launching branded direct-to-consumer campaigns to showcase DAYBUE benefits and utilising various communication channels to bring DAYBUE clinical data to life.
Acadia also provided guidance for full-year US-only net sales in 2025 of between US$380 million and US$405 million. Neuren said that outside the US, first sales in Canada are anticipated in the third quarter of 2025, pending price negotiations. Acadia also expects initial revenues from managed access programs in certain European countries this year.
Neuren said anticipated royalties are $56.2 million for the full year 2024, up 110 per cent from 2023, and $18.7 million for the fourth quarter 2024, up 46 per cent from 2023. It anticipates royalties of between $62 million and $67 million for the full year 2025.